BIIB241018P210000
- 19.20
- 0.000.00%
Biogen Newsroom
Eli Lilly's Alzheimer's Drug Raises Hopes but Faces Regulatory Hurdles in Europe
Eight Stocks Positioned for Short Sales – Oppenheimer Asset Management
Eli Lilly and Co (LLY.US) CEO: Its Alzheimer's drugs can play a "preventive" role.
Eli Lilly and Co's CEO told the United Kingdom Health Minister that their method of treating Alzheimer's disease can 'prevent' the disease.
Eli Lilly CEO Told UK Health Secretary Its Alzheimer's Treatment Could "Prevent" Disease: FT
Wells Fargo Maintains Biogen(BIIB.US) With Hold Rating, Maintains Target Price $225
Maintaining Hold on Biogen Amid Modest Growth and Cautious Outlook
Morgan Stanley Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $285
Wolfe's Tax Loss Selling Stocks Within Communications, Discretionary, Staples, Energy, Financials, Health Care
Biogen Reinstated at Market Perform at Raymond James on Leqembi Disappointment
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
Biogen Scores Breakthrough Status for Anti-rejection Transplant Medication
Raymond James Downgrades Biogen(BIIB.US) to Hold Rating
Biogen Analyst Ratings
Raymond James Downgrades Biogen to Market Perform
Express News | Raymond James resumed coverage of Biogen, with a rating consistent with the large cap.
J.P. Morgan Maintains Biogen(BIIB.US) With Hold Rating, Announces Target Price $220
Analysts Conflicted on These Healthcare Names: Biogen (BIIB) and Traws Pharma (TRAW)
Biogen: Felzartamab Receives Breakthrough Therapy Designation - Quick Facts
Biogen's Stock Bounces After Treatment for Kidney-transplant Rejection Gets FDA Boost
Express News | Biogen Inc - to Initiate Phase 3 Trials for Felzartamab in 2025